In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Exclusive interviews with the CEOs at bluebird bio and Voyager Therapeutics about what could be a standout 2023 for both firms, as well as a look at the life and career of Mads Øvlisen, former CEO of Novo Nordisk and father of CSR.

Flight Of The Navigator: Bluebird bio's Andrew Obenshain

For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.

Al Sandrock On His First Mission At Voyager: Cracking The Tau Alzheimer’s Puzzle

Interview: Twelve months on from exiting Biogen, Al Sandrock is once again leading innovation in neuroscience, and hopes to crack the tau nut in Alzheimer’s and prove that Voyager’s next-generation gene therapy system will be a breakthrough.

Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR

When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.

Pfizer's Dolsten On Finding Ways To “Accelerate External Science”

Worldwide President of R&D Mikael Dolsten talked to Scrip about Pfizer's busy business development track record and the company's ambition to maintain its leadership in breast cancer.

Chapter sponsored by:

WCG logo

Driving More Effective Clinical Trials To Impact Lives

Sam Srivastava, CEO of WCG

The blending of science and technology is changing the life sciences industry at an extraordinary pace. Clinical trials are getting more complex, both in design and in their conduct. Never before have we seen the growing number of systems and new technologies used within clinical research.

Download Now 

About WCG

WCG optimizes the clinical trial process by providing solutions to overcome the greatest threats to clinical innovation – so research accelerates, therapies emerge, global health advances, and patients have hope.

Learn More »

Outlook 2023 e-Book

Outlook 2023 cover

Download a PDF copy of the Outlook 2023 collection, including Scrip 100 league tables.